Belmont Capital, LLC Ab Cellera Biologics Inc. Transaction History
Belmont Capital, LLC
- $364 Million
- Q1 2024
A detailed history of Belmont Capital, LLC transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Belmont Capital, LLC holds 260,000 shares of ABCL stock, worth $699,400. This represents 0.32% of its overall portfolio holdings.
Number of Shares
260,000
Previous 510,000
49.02%
Holding current value
$699,400
Previous $2.91 Million
59.58%
% of portfolio
0.32%
Previous 1.25%
Shares
5 transactions
Others Institutions Holding ABCL
# of Institutions
170Shares Held
120MCall Options Held
264KPut Options Held
254K-
Baker Bros. Advisors LP New York, NY27.5MShares$74 Million1.58% of portfolio
-
Baillie Gifford & CO23.2MShares$62.4 Million0.08% of portfolio
-
Voya Investment Management LLC Atlanta, GA10.6MShares$28.6 Million0.06% of portfolio
-
Capital World Investors Los Angeles, CA8.35MShares$22.5 Million0.01% of portfolio
-
Credit Suisse Ag Zurich, V84.55MShares$12.2 Million0.02% of portfolio
About AbCellera Biologics Inc.
- Ticker ABCL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 285,139,008
- Market Cap $767M
- Description
- AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...